



GOVERNMENT OF BERMUDA

---

**Registry General**

**Patent Application Advertisements**

PATENT AND DESIGN ACT 1930

**GOVERNMENT NOTICE NO.: 11**

Notice is hereby given that person who has grounds of Opposition to the registration of any of the Patent Applications advertised herein according to the Invention claimed under the heading "Patent Applications advertised before Registration" may within two months from the date of this publication, lodge with the Registrar, Notice of Opposition in writing in duplicate accompanied by a fee of \$45 payable either by cheque made payable to the Accountant General, by cash or by Revenue Stamp obtainable at the Office of the Accountant General.

Please further note that Patent Applications filed in Bermuda for registration are shown with the Official Number accompanied by letters BM. Patent applications registered in the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters UK. Patent Applications registered in the European Union designating the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters EP.

---

**PATENT APPLICATIONS ADVERTISED BEFORE REGISTRATION**

**Patent No. 762EP**

**Description: COMPOUNDS AND CONJUGATES THEREOF**

On **25 August 2023**, **MedImmune Limited**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **MedImmune Limited**, claims to be the Inventor or Proprietor of an invention: **COMPOUNDS AND CONJUGATES THEREOF**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MedImmune Limited** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 763EP**

### **Description: PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291**

On **8 September 2023**, **AstraZeneca AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an invention: **PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 764EP**

### **Description: MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR**

On **13 September 2023**, **Vertex Pharmaceuticals Incorporated**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Vertex Pharmaceuticals Incorporated**, claims to be the Inventor or Proprietor of an invention: **MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR,** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Vertex Pharmaceuticals Incorporated** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 765EP**

### **Description: USE OF C-MET INHIBITORS TO TREAT CANCERS HARBOURING MET MUTATIONS**

On **6 November 2023**, **AstraZeneca AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an invention: **USE OF C-MET INHIBITORS TO TREAT CANCERS HARBOURING MET MUTATIONS**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 766EP**

### **Description: TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND USES THEREOF**

On **31, January 2024**, **Acceleron Pharma Inc.**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Acceleron Pharma Inc.**, claims to be the Inventor or Proprietor of an invention **TGF-BETA RECEPTOR TYPE II FUSION PROTEINS AND USES THEREOF**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Acceleron Pharma Inc.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 767EP**

### **Description: COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER**

On **16 February 2024**, **AstraZeneca AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an invention **COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 768EP**

### **Description: PURIFICATION OF RECOMBINANTLY PRODUCED POLYPEPTIDES**

On **1 March 2024**, **MedImmune LLC and MedImmune Limited**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **MedImmune LLC and MedImmune Limited**, claims to be the Inventor or Proprietor of an invention **PURIFICATION OF RECOMBINANTLY PRODUCED POLYPEPTIDES** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MedImmune LLC and MedImmune Limited**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 769EP**

### **Description: METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS**

On **13 March 2024**, **Merck Sharp & Dohme LLC**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Merck Sharp & Dohme LLC**, claims to be the Inventor or Proprietor of an **METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 770EP**

### **Description: STABLE ANTI-IFNAR1 FORMULATION**

On **20 March 2024**, **AstraZeneca AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an **STABLE ANTI-IFNAR1 FORMULATION** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 771EP**

### **Description: PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP**

On 1 April 2024, **Daiichi Sankyo Company, Limited**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Daiichi Sankyo Company, Limited** claims to be the Inventor or Proprietor of an **PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Daiichi Sankyo Company, Limited**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

## **Patent No. 772EP**

### **Description: 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS**

On 17 April 2024, **AstraZeneca AB**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **AstraZeneca AB**, claims to be the Inventor or Proprietor of an **2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AstraZeneca AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**